Martha Donoghue, MD
Associate Director of Pediatric Oncology and Rare Cancers
FDA
Dr. Donoghue oversees advances made in drug development for rare cancers in both adult and pediatric patients. She’s worked at the FDA for 14 years, starting as a clinical reviewer in the Division of Biologic Oncology Products, as well as in the Neuro-oncology, Pediatric Solid Tumor, and Rare Tumors team in the Division of Oncology Products 2. During her time with the FDA, Dr. Donoghue worked on initiatives and drug approvals for the treatment of pediatric and rare cancers, and she contributed to creating the Oncology Subcommittee of the FDA Pediatric Review Committee, pediatric oncology FDA guidance, and the Pediatric Research Equity Act.